Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALTO-101 in schizophrenia with cognitive impairment
NCT06502964Phase 2Recruiting
- Sponsor
- Alto Neuroscience
- Start
- Jun 2024
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ALTO-101 in schizophrenia, sponsored by Alto Neuroscience. Started Jun 2024; status: recruiting.
02
Drugs
ALTO-101
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06502964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06502964.